All In Biotech

Investigational drug · Phase 3

AZD0120

Also called: GC012F

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

9 still active

All registered trials

12

Any phase or sponsor naming "AZD0120"

First trial start

2023

Jul 20, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AZD0120", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Newly Diagnosed Multiple Myeloma (NDMM)
  • Relapsed AL Amyloidosis
  • Refractory AL Amyloidosis
  • Light Chain Amyloidosis
  • Amyloidosis
  • Relapsed/Refractory Multiple Myeloma
  • Refractory Systemic Lupus Erythematosus
  • Lupus Erythematosus, Systemic
  • Systemic Sclerosis
  • Idiopathic Inflammatory Myopathies

Approved drugs for the same conditions: Multiple myeloma · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "AZD0120" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.